Rheumatic Diseases Associated With Posterior Reversible Encephalopathy Syndrome.
Journal
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
ISSN: 1536-7355
Titre abrégé: J Clin Rheumatol
Pays: United States
ID NLM: 9518034
Informations de publication
Date de publication:
01 Dec 2021
01 Dec 2021
Historique:
pubmed:
1
7
2020
medline:
26
11
2021
entrez:
1
7
2020
Statut:
ppublish
Résumé
Posterior reversible encephalopathy syndrome (PRES) is an acute neurological syndrome. There are many reports of PRES occurring in the setting of rheumatic diseases. However, it remains uncertain whether rheumatic diseases are truly a risk factor for PRES, as the literature consists of case reports and small clinical series. Here, we evaluated the relationship between PRES and the rheumatic diseases, using a large population-based data set as the reference. We conducted a medical records review of hospitalizations in the United States during 2016 with a diagnosis of PRES. Hospitalizations were selected from the National Inpatient Sample. International Classification of Diseases, 10th Revision, Clinical Modification codes were used to identify rheumatic diseases. A multivariate logistic regression analysis was used to calculate odds ratios (ORs) for the association of PRES and rheumatic diseases. There were 3125 hospitalizations that had a principal billing diagnosis of PRES. Multivariate logistic regression revealed the multiple independent associations with PRES. The demographic and nonrheumatic associations included acute renal failure (OR, 1.52), chronic renal failure (OR, 12.1), female (OR, 2.28), hypertension (OR, 8.73), kidney transplant (OR, 1.97), and preeclampsia/eclampsia (OR, 11.45). Rheumatic associations with PRES included antineutrophil cytoplasmic antibody-associated vasculitis (OR, 9.31), psoriatic arthritis (OR, 4.61), systemic sclerosis (OR, 6.62), systemic lupus erythematosus (SLE) nephritis (OR, 7.53), and SLE without nephritis (OR, 2.38). This analysis represents the largest sample to date to assess PRES hospitalizations. It confirms that several rheumatic diseases are associated with PRES, including antineutrophil cytoplasmic antibody-associated vasculitis, systemic sclerosis, SLE, and psoriatic arthritis. Acute and unexplained central nervous system symptoms in these patient populations should prompt consideration of PRES.
Identifiants
pubmed: 32604240
pii: 00124743-202112000-00023
doi: 10.1097/RHU.0000000000001470
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e391-e394Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med . 1996;334:494–500.
Gatla N, Annapureddy N, Sequeira W, et al. Posterior reversible encephalopathy syndrome in systemic lupus erythematosus. J Clin Rheumatol . 2013;19:334–340.
Magnano MD, Bush TM, Herrera I, et al. Reversible posterior leukoencephalopathy in patients with systemic lupus erythematosus. Semin Arthritis Rheum . 2006;35:396–402.
Lai CC, Chen WS, Chang YS, et al. Clinical features and outcomes of posterior reversible encephalopathy syndrome in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) . 2013;65:1766–1774.
Shaharir S, Remli R, Marwan A, et al. Posterior reversible encephalopathy syndrome in systemic lupus erythematosus: pooled analysis of the literature reviews and report of six new cases. Lupus . 2013;22:492–496.
Jung SM, Moon SJ, Kwok SK, et al. Posterior reversible encephalopathy syndrome in Korean patients with systemic lupus erythematosus: risk factors and clinical outcome. Lupus . 2013;22:885–891.
Arteaga-Müller G, Camara-Lemarroy CR, Rizo-Topete L, et al. Granulomatosis with polyangiitis and posterior reversible encephalopathy syndrome. J Neurol Sci . 2016;15:204–205.
Lioger B, Diot E, Ebbo M, et al., Société Nationale Française de Médecine interne (SNFMI) and the CRI (Club Rhumatismes et Inflammation). Posterior reversible encephalopathy syndrome and systemic vasculitis: report of six cases. Clin Exp Rheumatol . 2016;34(3 suppl 97):S7–S11.
Marra AM, Barilaro G, Villella V, et al. Eosinophilic granulomatosis with polyangiitis (EGPA) and PRES: a case-based review of literature in ANCA-associated vasculitides. Rheumatol Int . 2015;35:1591–1595.
Min L, Zwerling J, Ocava LC, et al. Reversible posterior leukoencephalopathy in connective tissue diseases. Semin Arthritis Rheum . 2006;35:388–395.
Ohta T, Sakano T, Shiotsu M, et al. Reversible posterior leukoencephalopathy in a patient with Wegener granulomatosis. Pediatr Nephrol . 2004;19:442–444.
Patel UV, Patel NJ. Posterior reversible leukoencephalopathy syndrome as a presenting manifestation of p-ANCA-associated vasculitis. BMJ Case Rep . 2014;22:2014.
Tajima Y, Matsumoto A. Reversible posterior leukoencephalopathy syndrome in p-ANCA–associated vasculitis. Intern Med . 2006;45:1169–1171.
Renard D, Westhovens R, Vandenbussche E, et al. Reversible posterior leucoencephalopathy during oral treatment with methotrexate. J Neurol . 2004;251:226–228.
Ocek L, Sener U, Demirtas BS, et al. Central-variant posterior reversible encephalopathy due to sulfasalazine: a case report. Med Princ Pract . 2015;24:578–580.
Merayo-Chalico J, Apodaca E, Barrera-Vargas A, et al. Clinical outcomes and risk factors for posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a multicentric case-control study. J Neurol Neurosurg Psychiatry . 2016;87:287–294.
Liu B, Zhang X, Zhang FC, et al. Posterior reversible encephalopathy syndrome could be an underestimated variant of “reversible neurological deficits” in systemic lupus erythematosus. BMC Neurol . 2012;12:152.
Camara-Lemarroy CR, Escobedo-Zúñiga N, Villarreal-Garza E, et al. Posterior reversible leukoencephalopathy syndrome (PRES) associated with severe eclampsia: clinical and biochemical features. Pregnancy Hypertens . 2017;7:44–49.
Dong XY, Bai CB, Nao JF. Clinical and radiological features of posterior reversible encephalopathy syndrome in patients with pre-Eclampsia and Eclampsia. Clin Radiol . 2017;72:887–895.
Brewer J, Owens MY, Wallace K, et al. Posterior reversible encephalopathy syndrome in 46 of 47 patients with eclampsia. Am J Obstet Gynecol . 2013;208:468.e1–468.e6.
Leroux G, Sellam J, Costedoat-Chalumeau N, et al. Posterior reversible encephalopathy syndrome during systemic lupus erythematosus: four new cases and review of the literature. Lupus . 2008;17:139–147.
Varaprasad IR, Agrawal S, Prabu VN, et al. Posterior reversible encephalopathy syndrome in systemic lupus erythematosus. J Rheumatol . 2011;38:1607–1611.
Gratton D, Szapary P, Goyal K, et al. Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature. Arch Dermatol . 2011;147:1197–1202.
Zekić T, Benić MS, Antulov R, et al. The multifactorial origin of posterior reversible encephalopathy syndrome in cyclophosphamide-treated lupus patients. Rheumatol Int . 2017;37:2105–2114.
Jabrane M, Lahcen ZA, Fadili W, et al. A case of PRES in an active lupus nephritis patient after treatment of corticosteroid and cyclophosphamide. Rheumatol Int . 2015;35:935–938.